Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells

Uterine cervical adenocarcinoma has a poor clinical prognosis when compared with squamous cell carcinoma. Therefore, the development of new treatment strategies for uterine cervical adenocarcinoma is necessary. Src is a proto-oncogene that is important in cancer progression. Dasatinib is a Src inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Takiguchi, Eri, Nishimura, Masato, Mineda, Ayuka, Kawakita, Takako, Abe, Akiko, Irahara, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647549/
https://www.ncbi.nlm.nih.gov/pubmed/29067110
http://dx.doi.org/10.3892/etm.2017.5061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647549/
https://www.ncbi.nlm.nih.gov/pubmed/29067110
http://dx.doi.org/10.3892/etm.2017.5061

Ejemplares similares